Oxford Lymphoid Disorders Study Group
The Oxford Lymphoid Disorders Study Group (OLDSG) was launched in September 2020, and brings together a network of researchers and clinicians from across the University of Oxford and Oxford University Hospitals Trust.
At present, around 3-4% of people will develop either lymphoma or Chronic Lymphocytic Leukaemia (CLL) during their lifetime. Together, lymphoma and CLL represent the commonest blood cancer by some margin.
The purpose of OLDSG is to:
- to increase the visibility of lymphoid disorder research in the university
- to foster collaborations between clinicians and laboratory-based scientists leading to high quality translational projects
- to interact with patients and the public at all levels of project development to deliver research which impacts directly on patient need
Group members work on a range of issues relating to lymphoid disorders, haematology, immunology, molecular diagnostics and late effects research.
Group members
-
Graham Collins
Haematologist and Group Chair
-
Toby Eyre
Haematologist
-
David Cutter
Radiotherapist and Epidemiologist
-
Gareth Turner
Pathologist
-
Mariolina Salio
Immunologist
-
Anna Schuh
Molecular Diagnostics and Chronic Lymphocytic Leukemia lead
-
Brian Nicholson
Primary Care Physician and Early Detection
-
Penny Clark
Patient Representitive
BLOOD CANCER NEWS
Public talk: Using blood tests to detect cancer
7 December 2022
Organised by the NIHR Oxford Biomedical Research Centre, Professor Mark Middleton and patient representative Sue Duncombe discuss how cancer blood tests are being assessed and how they may change how cancer is diagnosed in the NHS.
Researchers make miniature ‘bone marrows in a dish’ to improve anti-cancer treatments
25 November 2022
Scientists from the University of Oxford's MRC Weatherall Institute of Molecular Medicine and the University of Birmingham have made the first bone marrow ‘organoids’ that include all the key components of human marrow. This technology allows for the screening of multiple anti-cancer drugs at the same time, as well as testing personalised treatments for individual cancer patients.